Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.

The Journal of infectious diseases - 17 Sept 2021

Ferreira Isabella A T M, Kemp Steven A, Datir Rawlings, Saito Akatsuki, Meng Bo, Rakshit Partha, Takaori-Kondo Akifumi, Kosugi Yusuke, Uriu Keiya, Kimura Izumi, Shirakawa Kotaro, Abdullahi Adam, Agarwal Anurag, Ozono Seiya, Tokunaga Kenzo, Sato Kei, Gupta Ravindra K

Abstract excerpt

The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to COVID-19 Vaccines

Share to Immune Evasion

Share to Serine Endopeptidases

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 34260717
DOI: 10.1093/infdis/jiab368
PMCID: PMC8420622

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.PMID 34260717Read ↗

SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthroughSemantic proximity Read ↗

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodiesSemantic proximity Read ↗

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.Semantic proximity Read ↗

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsSemantic proximity Read ↗

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodiesSemantic proximity Read ↗

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.Semantic proximity Read ↗

A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance MutationsSemantic proximity Read ↗

Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152Semantic proximity Read ↗

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodiesSemantic proximity Read ↗

A novel B.1.1.523 SARS-CoV-2 variant that combines many spike mutations linked to immune evasion with current variants of concernSemantic proximity Read ↗

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variantsSemantic proximity Read ↗

Antibody evasion by the P.1 strain of SARS-CoV-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.